---
layout: default
title: Raltegravir
parent: 僅模型預測 (L5)
nav_order: 54
evidence_level: L5
indication_count: 3
---

# Raltegravir
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# RALTEGRAVIR: Repurposing Assessment Pending — Evidence Pack Incomplete

## One-Sentence Summary

RALTEGRAVIR (DrugBank: DB06817) is a known antiretroviral agent; however, the current evidence pack contains no TxGNN-predicted new indications, no mechanism of action data, and no safety records.
Without predicted indications or supporting evidence, a full drug repurposing evaluation cannot be completed at this stage.
This report documents the data gaps and outlines the remediation steps required before proceeding.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current evidence pack |
| Predicted New Indication | None — TxGNN predictions not yet generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not assessable |
| Germany Market Status | Not found (0 authorizations in current data) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Three critical data layers are missing — TxGNN repurposing predictions, mechanism of action, and safety profile — making it impossible to evaluate any new therapeutic indication at this time.

**To proceed, the following is needed:**

- **Run TxGNN inference** for RALTEGRAVIR (DB06817) to generate candidate predicted indications with confidence scores
- **Retrieve MOA from DrugBank** via API (DB06817) — currently classified as a data gap of High severity; required for mechanistic plausibility analysis
- **Obtain package insert** (TFDA or EMA/BfArM source) to extract key warnings, contraindications, and drug–drug interactions — currently classified as a Blocking data gap
- **Verify Germany market status** via BfArM database — RALTEGRAVIR (brand: Isentress, MSD) holds EMA marketing authorisation; the current zero-result may reflect a query scope issue rather than true non-registration
- Once the above data is collected, re-generate this evidence pack (target version v5+) and re-run the full evaluation pipeline
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

